Prümmer O
Department of Internal Medicine III, University of Ulm, Germany.
Cancer. 1993 Mar 1;71(5):1828-34. doi: 10.1002/1097-0142(19930301)71:5<1828::aid-cncr2820710518>3.0.co;2-0.
Prolonged therapy with interferon (IFN) may lead to the formation of IFN antibodies.
Patients with renal cell carcinoma (n = 270) with advanced localized disease were randomized after complete tumor resection to receive treatment with adjuvant recombinant IFN-alpha-2a (rIFN-alpha 2a) (9 x 10(6) IU subcutaneously, three times per week for a maximum of 12 months) versus no treatment. Patients (IFN-treated group, 106 patients; control group, 97 patients) were monitored for the presence of rIFN-alpha 2a antibodies.
Of 86 IFN-treated patients observed for more than 2 months, 40 (47%) had IFN-alpha 2a-binding and 25 (29%) had IFN-alpha 2a-neutralizing antibodies developed within a median of 3 and 6 months, respectively. A distinct peak in binding antibody titers occurred at 6-9 months. Therapy-induced neutralizing antibodies were equally reactive with two other recombinant IFN-alpha-2 subtypes but poorly recognized natural IFN-alpha (IFN-alpha), recombinant IFN-alpha-1/alpha-8, and recombinant IFN-omega-1. The duration of remission and rate of relapse were independent of the antibody status, although neutralizing and most non-neutralizing antibodies correlated with a reduction in the IFN-induced increase in beta-2-microglobulin levels.
Patients treated with IFN-alpha 2a should be monitored for the presence and clinical relevance of IFN-alpha antibodies to determine those who could respond to alternative treatment.
干扰素（IFN）长期治疗可能导致IFN抗体形成。
270例局限性晚期肾细胞癌患者在肿瘤完全切除后随机分组，接受辅助性重组IFN-α-2a（rIFN-α 2a）治疗（皮下注射9×10⁶IU，每周3次，最多12个月）或不治疗。对患者（IFN治疗组106例；对照组97例）监测rIFN-α 2a抗体的存在情况。
在86例接受IFN治疗超过2个月的患者中，分别有40例（47%）在中位时间3个月时出现IFN-α 2a结合抗体，25例（29%）在中位时间6个月时出现IFN-α 2a中和抗体。结合抗体滴度在6 - 9个月出现明显峰值。治疗诱导的中和抗体与另外两种重组IFN-α-2亚型具有同等反应性，但对天然IFN-α（IFN-α）、重组IFN-α-1/α-8和重组IFN-ω-1的识别能力较差。缓解持续时间和复发率与抗体状态无关，尽管中和抗体和大多数非中和抗体与IFN诱导的β-2微球蛋白水平升高的降低相关。
接受IFN-α 2a治疗的患者应监测IFN-α抗体的存在情况及其临床相关性，以确定那些可能对替代治疗有反应的患者。
